Evaluate toxicity of pyrazoloacridine. Weekly prior to each treatment cycle. [clinicaltrials_resource:f35cf3782fbcce7b0fe99adb33fe084d]
Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Evaluate toxicity of pyrazoloacridine. Weekly prior to each treatment cycle. [clinicaltrials_resource:f35cf3782fbcce7b0fe99adb33fe084d]
Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.
Bio2RDF identifier
f35cf3782fbcce7b0fe99adb33fe084d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:f35cf3782fbcce7b0fe99adb33fe084d
measure [clinicaltrials_vocabulary:measure]
Evaluate toxicity of pyrazoloacridine.
time frame [clinicaltrials_vocabulary:time-frame]
Weekly prior to each treatment cycle.
description
Pyrazoloacridine 750 mg/m2 by ...... sease or prohibitive toxicity.
identifier
clinicaltrials_resource:f35cf3782fbcce7b0fe99adb33fe084d
title
Evaluate toxicity of pyrazoloacridine. Weekly prior to each treatment cycle.
@en
type
label
Evaluate toxicity of pyrazoloa ...... cf3782fbcce7b0fe99adb33fe084d]
@en